News | September 17, 2025
Lilly to build $5 billion manufacturing facility in Virginia
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
